Takeda and Molecular Templates announce cancer research alliance

Takeda has announced a new partnership with Molecular Templates that aims to generate new approaches to treating cancer.

The multi-target research and licensing collaboration will apply Molecular Templates' engineered toxin bodies technology platform to potential therapeutic targets provided by Takeda through a joint scientific committee.

Under the terms of the deal, Takeda will make an equity investment in Molecular Templates, which will be eligible to receive upfront payments, development and commercial milestone fees, and royalties on the sales of commercial products developed through the collaboration.

Takeda will also appoint a director to Molecular Templates' board, and will have the right to exercise exclusive options to obtain licences to any products created.

Dr Christopher Arendt, head of the oncology and immunology unit at Takeda, said: "The announcement of today's collaboration with Molecular Templates allows us to extend this partnership and leverage their potentially groundbreaking approach to address additional tumour types, including solid tumours."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.